{"id":4418,"date":"2019-03-26T05:37:16","date_gmt":"2019-03-26T05:37:16","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/?post_type=study_trials&#038;p=4418"},"modified":"2019-03-26T05:37:16","modified_gmt":"2019-03-26T05:37:16","slug":"essai-de-phase-ii-evaluant-le-cobimetinib-en-monotherapie-chez-des-adultes-atteints-dhistiocytose-systemique","status":"publish","type":"study_trials","link":"https:\/\/www.erdheim-chester.org\/fr\/study_trials\/phase-2-trial-of-single-agent-cobimetinib-for-adults-with-systemic-histiocytosis\/","title":{"rendered":"Essai de phase II sur le cobim\u00e9tinib en monoth\u00e9rapie chez des adultes atteints d'histiocytose syst\u00e9mique"},"content":{"rendered":"<p><strong>Objectif de l'\u00e9tude :<\/strong> Il s'agit d'un essai clinique portant sur un nouveau m\u00e9dicament destin\u00e9 au traitement des patients atteints de la maladie d'Erdheim-Chester dont le tissu ECD (1) ne pr\u00e9sente PAS la mutation BRAF ou (2) dont le tissu pr\u00e9sente la mutation BRAF, mais qui n\u2019ont pas acc\u00e8s \u00e0 un inhibiteur de BRAF ou qui ont d\u00e9j\u00e0 pris un inhibiteur de BRAF et ne le tol\u00e8rent pas.<\/p>\n<p><strong>Parrain :<\/strong> Genentech et le Memorial Sloan Kettering Cancer Center<\/p>\n<p><strong>Coordonn\u00e9es pour l'essai :<\/strong> Dr Eli L. Diamond, (212) 610-0243 ou diamone1@mskcc.org<\/p>\n<p><strong>Participation demand\u00e9e au patient :<\/strong> Tout patient atteint d\u2019un cancer colorectal avanc\u00e9 (ECD) qui est BRAF-n\u00e9gatif ou qui est BRAF-positif et ne peut pas recevoir ou tol\u00e9rer un inhibiteur de BRAF. Les patients pr\u00e9sentant certains probl\u00e8mes oculaires ou cardiaques peuvent ne pas \u00eatre \u00e9ligibles et devront subir des examens de s\u00e9lection (qui peuvent souvent \u00eatre effectu\u00e9s pr\u00e8s de chez eux). L'\u00e9tude n\u00e9cessite des visites mensuelles au MSKCC, bien qu'apr\u00e8s un an de participation \u00e0 l'essai, celles-ci puissent avoir lieu tous les deux mois.<\/p>\n<p><strong>Centres connus acceptant des patients atteints d'ECD dans le cadre de l'essai :<\/strong> Memorial Sloan-Kettering, New York, NY, \u00c9tats-Unis<\/p>\n<p><strong>Identifiant ClinicalTrials.gov :<\/strong> NCT02649972<\/p>","protected":false},"excerpt":{"rendered":"<p>Study Objective: This is a clinical trial of a new medication to treat patients with Erdheim-Chester disease whose ECD tissue (1) does NOT have the BRAF mutation or (2) whose [&hellip;]<\/p>\n","protected":false},"featured_media":0,"parent":0,"menu_order":0,"template":"","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","cybocfi_hide_featured_image":"","wds_primary_study_trials_cat":0,"_links_to":"","_links_to_target":""},"study_trials_cat":[32],"class_list":["post-4418","study_trials","type-study_trials","status-publish","hentry","study_trials_cat-drug-trial"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/study_trials\/4418","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/study_trials"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/types\/study_trials"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/media?parent=4418"}],"wp:term":[{"taxonomy":"study_trials_cat","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/fr\/wp-json\/wp\/v2\/study_trials_cat?post=4418"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}